
Michael Roost Clausen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8721448/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. European Journal of Cancer, 2018, 93, 57-68.	1.3	90
2	The Danish National Lymphoma Registry: Coverage and Data Quality. PLoS ONE, 2016, 11, e0157999.	1.1	66
3	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European Journal of Cancer, 2017, 75, 195-203.	1.3	65
4	Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study. European Journal of Cancer, 2018, 99, 86-96.	1.3	59
5	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large Bâ€cell lymphoma is associated with poor outcomes and a high frequency of secondary <scp>CNS</scp> involvement. British Journal of Haematology, 2016, 175, 876-883.	1.2	34
6	SARSâ€CoVâ€2 infection among patients with haematological disorders: Severity and oneâ€month outcome in 66 Danish patients in a nationwide cohort study. European Journal of Haematology, 2021, 106, 72-81.	1.1	21
7	First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas. Blood, 2019, 134, 758-758.	0.6	17
8	Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. Haematologica, 2020, 105, 2432-2439.	1.7	16
9	The Combination of Pixantrone, Etoposide, Bendamustine and, in CD2O+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial). Blood. 2016, 128, 1782-1782.	0.6	10
10	Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. Clinical Epidemiology, 2019, Volume 11, 987-996.	1.5	5
11	Depth of neutrophil nadir after first cycle of R-CHOP predicts outcome in diffuse large B-cell lymphoma – a nationwide population-based cohort study. Leukemia and Lymphoma, 2019, 60, 1950-1957.	0.6	2
12	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1874-1874.	0.6	2
13	Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura. European Journal of Haematology, 2011, 86, 256-259.	1.1	1
14	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 2015, 126, 3905-3905.	0.6	1
15	Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders. Acta Oncológica, 2022, 61, 500-504.	0.8	1
16	Prognostic significance of infectious episodes occurring during firstâ€line therapy for diffuse large Bâ€cell lymphoma ―A nationwide cohort study. Hematological Oncology, 2020, 38, 318-325.	0.8	0
17	Upfront Rituximab Maintenance after Induction Therapy Improves Outcome and Reduces the Risk of Histological Transformation in Patients with Follicular Lymphoma - Real World Data from a Danish Population-Based Cohort. Blood, 2016, 128, 1783-1783.	0.6	0
18	Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study. Leukemia and Lymphoma, 2022, , 1-10.	0.6	0

#	Article	IF	CITATIONS
19	Risk of diabetes and the impact on preexisting diabetes in lymphoma patients treated with steroid-containing immunochemotherapy. Blood Advances, O, , .	2.5	0